CytomX Therapeutics, Inc. (CTMX): Price and Financial Metrics


CytomX Therapeutics, Inc. (CTMX): $5.14

-0.05 (-0.96%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

CTMX POWR Grades


  • CTMX scores best on the Value dimension, with a Value rank ahead of 68.17% of US stocks.
  • CTMX's strongest trending metric is Momentum; it's been moving down over the last 51 weeks.
  • CTMX's current lowest rank is in the Momentum metric (where it is better than 4.42% of US stocks).

CTMX Stock Summary

  • Of note is the ratio of CytomX Therapeutics Inc's sales and general administrative expense to its total operating expenses; just 13.77% of US stocks have a lower such ratio.
  • Revenue growth over the past 12 months for CytomX Therapeutics Inc comes in at -22.04%, a number that bests only 11.43% of the US stocks we're tracking.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for CTMX comes in at -36.26% -- higher than that of just 8.15% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to CytomX Therapeutics Inc, a group of peers worth examining would be GLYC, MEIP, SRPT, JNCE, and VYGR.
  • CTMX's SEC filings can be seen here. And to visit CytomX Therapeutics Inc's official web site, go to www.cytomx.com.

CTMX Valuation Summary

  • In comparison to the median Healthcare stock, CTMX's price/earnings ratio is 114.25% lower, now standing at -5.2.
  • CTMX's price/sales ratio has moved down 56.3 over the prior 72 months.
  • Over the past 72 months, CTMX's EV/EBIT ratio has gone up 14.3.

Below are key valuation metrics over time for CTMX.

Stock Date P/S P/B P/E EV/EBIT
CTMX 2021-08-31 5.0 2.5 -5.2 -1.5
CTMX 2021-08-30 5.0 2.5 -5.1 -1.5
CTMX 2021-08-27 5.1 2.6 -5.3 -1.6
CTMX 2021-08-26 5.0 2.5 -5.1 -1.4
CTMX 2021-08-25 4.9 2.5 -5.1 -1.4
CTMX 2021-08-24 4.9 2.5 -5.1 -1.4

CTMX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CTMX has a Quality Grade of D, ranking ahead of 23.09% of graded US stocks.
  • CTMX's asset turnover comes in at 0.169 -- ranking 213th of 680 Pharmaceutical Products stocks.
  • TVTX, LEXX, and ORGS are the stocks whose asset turnover ratios are most correlated with CTMX.

The table below shows CTMX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.169 1 -0.872
2021-03-31 0.170 1 -0.944
2020-12-31 0.255 1 -0.424
2020-09-30 0.237 1 -0.610
2020-06-30 0.219 1 -0.636
2020-03-31 0.200 1 -0.554

CTMX Price Target

For more insight on analysts targets of CTMX, see our CTMX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $13.00 Average Broker Recommendation 1.5 (Moderate Buy)

CTMX Stock Price Chart Interactive Chart >

Price chart for CTMX

CTMX Price/Volume Stats

Current price $5.14 52-week high $10.05
Prev. close $5.19 52-week low $4.28
Day low $5.10 Volume 376,600
Day high $5.25 Avg. volume 844,100
50-day MA $5.05 Dividend yield N/A
200-day MA $6.89 Market Cap 334.91M

CytomX Therapeutics, Inc. (CTMX) Company Bio


CytomX Therapeutics develops a novel class of antibody therapeutics based on its Probody technology platform that address clinically-validated cancer targets in immuno-oncology. The company was founded in 2008 and is based in San Francisco, California.


CTMX Latest News Stream


Event/Time News Detail
Loading, please wait...

CTMX Latest Social Stream


Loading social stream, please wait...

View Full CTMX Social Stream

Latest CTMX News From Around the Web

Below are the latest news stories about CytomX Therapeutics Inc that investors may wish to consider to help them evaluate CTMX as an investment opportunity.

CytomX Therapeutics Appoints Dr. Alan Ashworth to Board of Directors

SOUTH SAN FRANCISCO, Calif., Oct. 04, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody® technology platform, today announced the appointment of Alan Ashworth, Ph.D., FRS, a world-renowned expert in cancer research and a global leader in cancer therapy development, to the companys board of directors.

Intrado Digital Media | October 4, 2021

CytomX Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference

SOUTH SAN FRANCISCO, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated therapeutics based on its Probody ® technology platform, today announced that Sean McCarthy, D.Phil., president, chief executive officer, and chairman, will participate in a virtual fireside chat at the H.C. Wainwright 23 rd Annual Global Investment Conference, being held from September 13-15, 2021. In addition, management will be available for one-on-one meetings with investors who are registered to attend the conference.

Intrado Digital Media | September 7, 2021

The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck

Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 18) AbbVie Inc. (NYSE: ABBV ) Alkermes plc (NASDAQ: ALKS ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX ) Gilead Sciences, Inc. (NASDAQ: GILD ) GlaxoSmithKline plc (NYSE: GSK ) ( announced FDA approval for label expansion for its Jemperli) Novo Nordisk A/S (NYSE: NVO ) Innoviva, Inc. (NASDAQ: INVA ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI ) Omega Therapeutics, Inc. (NASDAQ: OMGA ) (IPOed July 30) Pfizer, Inc. (NYSE: PFE ) Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) ResMed Inc. (NYSE: RMD ) TScan Therapeutics, Inc. (NASDAQ: TCRX ) Virpax Pharmaceutical...

Benzinga | August 19, 2021

CytomX Therapeutics Announces New Employment Inducement Grants

SOUTH SAN FRANCISCO, Calif., Aug. 17, 2021 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated antibody therapeutics based on its Probody® technology platform, today announced that on August 16, 2021, the Company granted seven new employees options to purchase a total of 172,600 shares of the Companys common stock at an exercise price per share equal to $4.81, which was the closing trading price on August 16, 2021, the date of the grant.

Intrado Digital Media | August 17, 2021

The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma

Here''s a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (NASDAQ: ADGI ) (IPOed Friday) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Cytek Biosciences, Inc. (NASDAQ: CTKB ) Dynavax Technologies Corporation (NASDAQ: DVAX ) Eliem Therapeutics, Inc. (NASDAQ: ELYM ) (IPOed Monday) Erasca, Inc. (NASDAQ: ERAS ) (IPOed July 16) Fulcrum Therapeutics, Inc. (NASDAQ: FULC ) (reacted to positive analyst actions following a positive clinical readout) IN8bio, Inc. (NASDAQ: INAB ) Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD ) Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI ) (announced second-quarter results) Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE ) Rani Therapeutics Holdings, ...

Benzinga | August 12, 2021

Read More 'CTMX' Stories Here

CTMX Price Returns

1-mo -1.72%
3-mo -10.92%
6-mo -39.74%
1-year -25.07%
3-year -66.60%
5-year -59.72%
YTD -21.53%
2020 -21.18%
2019 -44.97%
2018 -28.47%
2017 92.08%
2016 -47.34%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8899 seconds.